| Website | ospreypharma.com |
| Category | BioTech |
| Employees | |
| Founded | 1998 |
| Description | Inflammatory/immune disease medications |
| Total | $11M |
| Series A, 5/08 Burrill & Company Novo Nordisk Yasuda Enterprise Development GeneChem Therapeutics Venture Fund BDC Venture Capital Western Technology Investment | $11M |
| Series A, 5/09 |
Osprey Pharmaceuticals USA is a clinical stage company focused on the development of novel protein therapeutics for the treatment of inflammatory and immune diseases.
The company is advancing a pipeline of proprietary fusion protein therapeutics known as Leukocyte Population Modulators (LPMs) that are designed to selectively target and neutralize chemokine-activated leukocytes underlying a variety of inflammatory and immune diseases.
The Company’s lead candidate, CCL2-LPM targeting the CCR2 chemokine receptor expressed by certain pathologically activated leukocytes is in a Phase Ib clinical trial for the treatment of IgA nephropathy.
